Gencaro™ Potential Efficacy in Preventing Atrial Fibrillation Paper Published in JACC: Heart Failure ARCA biopharma, Inc. , a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the paper “Prevention of Atrial Fibrillation by Bucindolol is Dependent on the Beta-1 389 Arg/Gly Adrenergic Receptor Polymorphism” was published in the journal JACC: Heart Failure [http://heartfailure.onlinejacc.org/article.aspx?articleid=1691088], a ...
June 6, 2013 - Business Wire via Yahoo! Finance